Open AccessProduction of recombinant virus‐like particles from human papillomavirus types 6 and 11, and study of serological reactivities between HPV 6, 11, 16 and 45 by ELISA: implications for papillomavirus prevention and detection
Author(s) -
Touzé Antoine,
Dupuy Catherine,
Mahé Dominique,
Sizaret PierreYves,
Coursaget Pierre
Publication year - 1998
Publication title -
fems microbiology letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.899
H-Index - 151
eISSN - 1574-6968
pISSN - 0378-1097
DOI - 10.1111/j.1574-6968.1998.tb12899.x
Subject(s) - virology , capsid , virus , epitope , polyclonal antibodies , serology , recombinant dna , biology , virus like particle , genotype , monoclonal antibody , antiserum , antibody , gene , immunology , genetics
The L1 major capsid proteins of human papillomaviruses types 6 and 11 were expressed in insect cells using recombinant baculoviruses. These L1 proteins were shown to self‐assemble into virus‐like particles resembling papillomavirus virions as previously observed for HPV 16 and 45. However, we observed variations in the yield of virus‐like particles among the four genotypes investigated. This suggests that more than one strain of each genotype has to be investigated to obtain the high level of virus‐like particle production necessary to develop HPV vaccines or serological tests. Cross‐reactivities between HPV 6, 11, 16 and 45 were studied using polyclonal and monoclonal antibodies to virus‐like particles, L1 proteins and synthetic peptides. Although antisera react strongly against homologous virus‐like particles, there is evidence of some cross‐reactivity. This could be one of the explanations for the fact that antibodies to one genotype are detected in individuals infected with another genotype. This study also identified a linear epitope recognized by anti‐HPV 16 virus‐like particle sera.